“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
Executive Summary
A paradigm shift from maximum-tolerated dose to effective dose would result in more successful late-stage drug development, FDA Office of Clinical Pharmacology & Biopharmaceutics Pharmacometrics Team Leader Joga Gobburu, PhD, said April 23
You may also be interested in...
FDA Puts Dose Selection At Top Of Agenda For End-Of-Phase 2A Meetings
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance
FDA Puts Dose Selection At Top Of Agenda For End-Of-Phase 2A Meetings
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance
FDA Will Begin End-Of-Phase IIa Meetings Prior To January Guidance
FDA will begin a pilot program for end-of-Phase IIa meetings in advance of a draft guidance expected to be issued in early 2004